{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:49:14Z","timestamp":1792111754865,"version":"4.4.0"},"reference-count":210,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gut Pathog"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gastrointestinal (GI) infections, caused by pathogens such as\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    ,\n                    <jats:italic>Salmonella<\/jats:italic>\n                    sp.,\n                    <jats:italic>Shigella<\/jats:italic>\n                    sp., and\n                    <jats:italic>Clostridium difficile<\/jats:italic>\n                    , pose significant global health challenges due to their prevalence, severity, and increasing resistance to conventional treatments. While phage therapy offers a targeted, adaptable, and potentially safer approach for treating these infections, several challenges hinder its widespread clinical application. This review explores the current state of phage therapy for GI-associated infections, highlighting key obstacles such as phage stability in the harsh GI environment, host immune responses that can impede phage efficacy, phage-bacteria interactions, and bacterial adaptation mechanisms, such as mutations in phage receptors, which can lead to phage-insensitive mutants. Additionally, the specificity of phages to bacterial strains necessitates the development of diverse phage cocktails tailored to individual infections. The complex interactions between phages and the gut microbiome present challenges in ensuring that phage therapy does not disrupt beneficial gut bacteria. Despite these challenges, advances in phage isolation, genetic engineering, and delivery systems offer promising avenues to optimize phage therapy for GI infection. This review underscores the pharmacokinetics and pharmacodynamics of phage therapy while emphasizing the need for multidisciplinary approaches to overcome existing barriers and translate this innovative treatment into clinical practice. Accordingly, ongoing research is necessary to optimize phage delivery methods, develop effective phage combinations, and understand the interactions between phages and the gut microbiome to ensure safe and effective treatments.\n                  <\/jats:p>","DOI":"10.1186\/s13099-025-00735-y","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T10:54:11Z","timestamp":1754909651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Recent insights on challenges encountered with phage therapy against gastrointestinal-associated infections"],"prefix":"10.1186","volume":"17","author":[{"given":"Reem A.","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masarra M.","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania I.","family":"Shebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7608-850X","authenticated-orcid":false,"given":"Khaled M.","family":"Aboshanab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"18","key":"735_CR1","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.3390\/nu16183217","volume":"16","author":"D Liang","year":"2024","unstructured":"Liang D, et al. Global incidence of diarrheal Diseases\u2014An update using an interpretable predictive model based on XGBoost and SHAP: A systematic analysis. Nutrients. 2024;16(18):3217.","journal-title":"Nutrients"},{"issue":"11","key":"735_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.mpmed.2021.08.002","volume":"49","author":"S Ranasinghe","year":"2021","unstructured":"Ranasinghe S, Fhogartaigh CN. Bacterial gastroenteritis. Medicine. 2021;49(11):687\u201393.","journal-title":"Medicine"},{"key":"735_CR3","doi-asserted-by":"crossref","unstructured":"Holst MM. Contributing factors of foodborne illness outbreaks\u2014National outbreak reporting system, united states, 2014\u20132022. MMWR Surveillance Summaries, 2025 74(1):1-12.","DOI":"10.15585\/mmwr.ss7401a1"},{"key":"735_CR4","doi-asserted-by":"publisher","first-page":"1384164","DOI":"10.3389\/fmicb.2024.1384164","volume":"15","author":"A Subramanian","year":"2024","unstructured":"Subramanian A. Emerging roles of bacteriophage-based therapeutics in combating antibiotic resistance. Front Microbiol. 2024;15:1384164.","journal-title":"Front Microbiol"},{"key":"735_CR5","doi-asserted-by":"crossref","unstructured":"Cui L et al. A comprehensive review on phage therapy and phage-Based drug development. Antibiot (Basel), 2024;13(9).","DOI":"10.3390\/antibiotics13090870"},{"key":"735_CR6","doi-asserted-by":"publisher","first-page":"1428637","DOI":"10.3389\/fcimb.2024.1428637","volume":"14","author":"A Mayorga-Ramos","year":"2024","unstructured":"Mayorga-Ramos A, et al. Bacteriophage-mediated approaches for biofilm control. Front Cell Infect Microbiol. 2024;14:1428637.","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"735_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/antibiotics14060545","volume":"14","author":"BSI Supina","year":"2025","unstructured":"Supina BSI, Dennis JJ. The current landscape of Phage\u2013Antibiotic synergistic (PAS) interactions. Antibiotics. 2025;14(6):545.","journal-title":"Antibiotics"},{"key":"735_CR8","doi-asserted-by":"crossref","unstructured":"Liu C et al. Phage-Antibiotic therapy as a promising strategy to combat Multidrug-Resistant infections and to enhance antimicrobial efficiency. Antibiot (Basel), 2022;11(5).","DOI":"10.3390\/antibiotics11050570"},{"key":"735_CR9","doi-asserted-by":"publisher","first-page":"109736","DOI":"10.1016\/j.ijfoodmicro.2022.109736","volume":"374","author":"Y Enciso-Mart\u00ednez","year":"2022","unstructured":"Enciso-Mart\u00ednez Y, et al. Relevance of tracking the diversity of Escherichia coli pathotypes to reinforce food safety. Int J Food Microbiol. 2022;374:109736.","journal-title":"Int J Food Microbiol"},{"key":"735_CR10","unstructured":"WHO). W.H.O., Diarrhoeal disease. 2024."},{"issue":"1","key":"735_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.54117\/gjpas.v1i1.10","volume":"1","author":"K SULEIMAN","year":"2022","unstructured":"SULEIMAN K, et al. Bacterial diarrhea among infants in developing countries: an overview of diarrheagenic Escherichia coli (DEC). Gadau J Pure Allied Sci. 2022;1(1):73\u201381.","journal-title":"Gadau J Pure Allied Sci"},{"key":"735_CR12","doi-asserted-by":"crossref","unstructured":"Alum EU, Obeagu EI, Ugwu O. Curbing diarrhea in children below five years old: the sub-Saharan African standpoint. Volume 5. J. New Medical Innovations and Research; 2024;1.","DOI":"10.31579\/2767-7370\/083"},{"key":"735_CR13","doi-asserted-by":"publisher","first-page":"114823","DOI":"10.1016\/j.lwt.2023.114823","volume":"182","author":"L Walker","year":"2023","unstructured":"Walker L, Sun S, Thippareddi H. Growth comparison and model validation for growth of Shiga toxin-producing Escherichia coli (STEC) in ground beef. LWT. 2023;182:114823.","journal-title":"LWT"},{"issue":"1","key":"735_CR14","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1186\/s12879-020-05664-6","volume":"20","author":"RMM Khairy","year":"2020","unstructured":"Khairy RMM, et al. Prevalence, phylogeny, and antimicrobial resistance of Escherichia coli pathotypes isolated from children less than 5 years old with community acquired- diarrhea in upper Egypt. BMC Infect Dis. 2020;20(1):908.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"735_CR15","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1128\/JCM.00215-14","volume":"52","author":"A Mansour","year":"2014","unstructured":"Mansour A, et al. Diarrhea burden due to natural infection with enterotoxigenic Escherichia coli in a birth cohort in a rural Egyptian community. J Clin Microbiol. 2014;52(7):2595\u2013603.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"735_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/antibiotics12050880","volume":"12","author":"K Grudlewska-Buda","year":"2023","unstructured":"Grudlewska-Buda K, et al. Antibiotic resistance in selected emerging bacterial foodborne Pathogens\u2014An issue of concern?? Antibiotics. 2023;12(5):880.","journal-title":"Antibiotics"},{"key":"735_CR17","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s13197-020-04634-9","volume":"58","author":"M Sivakumar","year":"2021","unstructured":"Sivakumar M, et al. Extended-spectrum beta-lactamase (ESBL) producing and multidrug-resistant Escherichia coli in street foods: a public health concern. J Food Sci Technol. 2021;58:1247\u201361.","journal-title":"J Food Sci Technol"},{"key":"735_CR18","doi-asserted-by":"crossref","unstructured":"Nasrollahian S, Graham JP, Halaji M. A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli. Front Cell Infect Microbiol, 2024; 14:1387497.","DOI":"10.3389\/fcimb.2024.1387497"},{"issue":"6","key":"735_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.5455\/OVJ.2024.v14.i6.1","volume":"14","author":"SR Ayuti","year":"2024","unstructured":"Ayuti SR, et al. Tackling salmonellosis: A comprehensive exploration of risks factors, impacts, and solutions. Open Vet J. 2024;14(6):1313\u201329.","journal-title":"Open Vet J"},{"issue":"1","key":"735_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/antibiotics13010076","volume":"13","author":"B Lamichhane","year":"2024","unstructured":"Lamichhane B, et al. Salmonellosis: an overview of epidemiology, pathogenesis, and innovative approaches to mitigate the antimicrobial resistant infections. Antibiotics. 2024;13(1):76.","journal-title":"Antibiotics"},{"issue":"5","key":"735_CR21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/foods10050907","volume":"10","author":"O Ehuwa","year":"2021","unstructured":"Ehuwa O, Jaiswal AK, Jaiswal S. Salmonella, food safety and food handling practices. Foods. 2021;10(5):907.","journal-title":"Foods"},{"issue":"26","key":"735_CR22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.15585\/mmwr.mm7226a1","volume":"72","author":"MJ Delahoy","year":"2023","unstructured":"Delahoy MJ, et al. Preliminary incidence and trends of infections caused by pathogens transmitted commonly through Food - Foodborne diseases active surveillance network, 10 U.S. Sites, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(26):701\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"735_CR23","doi-asserted-by":"publisher","first-page":"2372364","DOI":"10.1080\/22221751.2024.2372364","volume":"13","author":"Z Wang","year":"2024","unstructured":"Wang Z, et al. Nationwide trends and features of human salmonellosis outbreaks in China. Emerg Microbes Infections. 2024;13(1):2372364.","journal-title":"Emerg Microbes Infections"},{"issue":"10","key":"735_CR24","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.3390\/jcm14103465","volume":"14","author":"P Patel","year":"2025","unstructured":"Patel P, et al. Updates and current knowledge on the common forms of gastroenteritis: A review. J Clin Med. 2025;14(10):3465.","journal-title":"J Clin Med"},{"issue":"5","key":"735_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/antibiotics10050493","volume":"10","author":"RA Youssef","year":"2021","unstructured":"Youssef RA, et al. Serotyping and antimicrobial resistance profile of enteric nontyphoidal Salmonella recovered from febrile neutropenic patients and poultry in Egypt. Antibiotics. 2021;10(5):493.","journal-title":"Antibiotics"},{"issue":"3","key":"735_CR26","doi-asserted-by":"publisher","first-page":"e02771","DOI":"10.1128\/spectrum.02771-21","volume":"10","author":"S Zeng","year":"2022","unstructured":"Zeng S, et al. Prevalence of chromosomally located Bla CTX-M-55 in Salmonella typhimurium ST34 isolates recovered from a tertiary hospital in guangzhou, China. Microbiol Spectr. 2022;10(3):e02771\u201321.","journal-title":"Microbiol Spectr"},{"key":"735_CR27","doi-asserted-by":"publisher","first-page":"104660","DOI":"10.1016\/j.microc.2020.104660","volume":"155","author":"ZR Nadi","year":"2020","unstructured":"Nadi ZR, et al. Evaluation of antibiotic resistance and prevalence of common Salmonella enterica serovars isolated from foodborne outbreaks. Microchem J. 2020;155:104660.","journal-title":"Microchem J"},{"key":"735_CR28","doi-asserted-by":"publisher","first-page":"648008","DOI":"10.3389\/fmicb.2021.648008","volume":"12","author":"Y-J Chang","year":"2021","unstructured":"Chang Y-J, et al. Changing antimicrobial resistance and epidemiology of non-typhoidal Salmonella infection in Taiwanese children. Front Microbiol. 2021;12:648008.","journal-title":"Front Microbiol"},{"issue":"14","key":"735_CR29","doi-asserted-by":"publisher","first-page":"e00591","DOI":"10.1128\/AEM.00591-19","volume":"85","author":"RG Ferrari","year":"2019","unstructured":"Ferrari RG, et al. Worldwide epidemiology of Salmonella serovars in animal-based foods: a meta-analysis. Appl Environ Microbiol. 2019;85(14):e00591\u201319.","journal-title":"Appl Environ Microbiol"},{"issue":"10","key":"735_CR30","doi-asserted-by":"publisher","first-page":"e0006779","DOI":"10.1371\/journal.pntd.0006779","volume":"12","author":"CD Britto","year":"2018","unstructured":"Britto CD, et al. A systematic review of antimicrobial resistance in Salmonella enterica serovar typhi, the etiological agent of typhoid. PLoS Negl Trop Dis. 2018;12(10):e0006779.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"735_CR31","doi-asserted-by":"publisher","first-page":"pmbio101128","DOI":"10.1128\/mBio.00482-18","volume":"9","author":"MM Levine","year":"2018","unstructured":"Levine MM, Simon R. The gathering storm: is untreatable typhoid fever on the way? MBio. 2018;9(2):pmbio101128\u201300482.","journal-title":"MBio"},{"key":"735_CR32","unstructured":"Shah SAA et al. Antimicrobial sensitivity pattern of Salmonella typhi: emergence of resistant strains. Cureus, 2020;12(11)."},{"key":"735_CR33","doi-asserted-by":"crossref","unstructured":"Chatham-Stephens K. Emergence of extensively drug-resistant Salmonella Typhi infections among travelers to or from Pakistan\u2014United states, 2016\u20132018. MMWR. Morbidity and Mortality Weekly Report; 2019;68.","DOI":"10.15585\/mmwr.mm6801a3"},{"issue":"11","key":"735_CR34","doi-asserted-by":"publisher","first-page":"e0007868","DOI":"10.1371\/journal.pntd.0007868","volume":"13","author":"Y Hooda","year":"2019","unstructured":"Hooda Y, et al. Molecular mechanism of Azithromycin resistance among typhoidal Salmonella strains in Bangladesh identified through passive pediatric surveillance. PLoS Negl Trop Dis. 2019;13(11):e0007868.","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"735_CR35","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.47391\/JPMA.8154","volume":"73","author":"N Safdar","year":"2023","unstructured":"Safdar N, et al. Pan Drug-Resistant Salmonella serovar Typhi septicaemia in A child: A case report. J Pak Med Assoc. 2023;73(9):1909\u201311.","journal-title":"J Pak Med Assoc"},{"key":"735_CR36","doi-asserted-by":"crossref","unstructured":"Punchihewage-Don AJ, Ranaweera PN, Parveen S. Defense mechanisms of Salmonella against antibiotics: a review. Front Antibiot, 2024.;3:1448796.","DOI":"10.3389\/frabi.2024.1448796"},{"issue":"1","key":"735_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12866-023-02963-1","volume":"23","author":"E Peh","year":"2023","unstructured":"Peh E, et al. Bacteriophage cocktail application for Campylobacter mitigation-from in vitro to in vivo. BMC Microbiol. 2023;23(1):209.","journal-title":"BMC Microbiol"},{"issue":"1","key":"735_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.mimet.2013.06.024","volume":"95","author":"N Jane\u017e","year":"2013","unstructured":"Jane\u017e N, Loc-Carrillo C. Use of phages to control Campylobacter spp. J Microbiol Methods. 2013;95(1):68\u201375.","journal-title":"J Microbiol Methods"},{"issue":"12","key":"735_CR39","first-page":"e07666","volume":"20","author":"EFS Authority","year":"2022","unstructured":"European Food Safety Authority (EFSA); European Centre for Disease Prevention and Control (ECDC). The European Union One Health 2022 Zoonoses Report. EFSA J. 2023;21(12):e8442.","journal-title":"EFSA J"},{"issue":"1","key":"735_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1556\/030.2024.02214","volume":"71","author":"S Maraki","year":"2024","unstructured":"Maraki S, et al. Prevalence and antimicrobial resistance of bacterial enteropathogens in crete, greece, during 2011\u20132022. Acta Microbiol Immunol Hung. 2024;71(1):69\u201375.","journal-title":"Acta Microbiol Immunol Hung"},{"issue":"2","key":"735_CR41","first-page":"402","volume":"12","author":"IA Bunduru\u0219","year":"2023","unstructured":"Bunduru\u0219 IA, et al. Overview of virulence and antibiotic resistance in Campylobacter spp. Livest Isolates Antibiot. 2023;12(2):402.","journal-title":"Livest Isolates Antibiot"},{"issue":"2","key":"735_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12223-020-00773-w","volume":"65","author":"I Nisa","year":"2020","unstructured":"Nisa I, et al. Shigella flexneri: an emerging pathogen. Folia Microbiol. 2020;65(2):275\u201391.","journal-title":"Folia Microbiol"},{"issue":"11","key":"735_CR43","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3390\/antibiotics11111653","volume":"11","author":"MZ Salleh","year":"2022","unstructured":"Salleh MZ, et al. Prevalence of Multidrug-Resistant and Extended-Spectrum Beta-Lactamase-Producing Shigella species in asia: A systematic review and Meta-Analysis. Antibiotics. 2022;11(11):1653.","journal-title":"Antibiotics"},{"issue":"1","key":"735_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00203-020-02034-3","volume":"203","author":"AA Shad","year":"2021","unstructured":"Shad AA, Shad WA. Shigella sonnei: virulence and antibiotic resistance. Arch Microbiol. 2021;203(1):45\u201358.","journal-title":"Arch Microbiol"},{"issue":"4","key":"735_CR45","doi-asserted-by":"publisher","first-page":"703","DOI":"10.13005\/bbra\/2953","volume":"18","author":"ST Ahamed","year":"2021","unstructured":"Ahamed ST, Giria N. Shigellosis and development of multiple antimicrobial resistance mechanisms of Shigella spp. Biosci Biotechnol Res Asia. 2021;18(4):703\u201318.","journal-title":"Biosci Biotechnol Res Asia"},{"issue":"3","key":"735_CR46","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.3390\/ijms24032448","volume":"24","author":"B Pakbin","year":"2023","unstructured":"Pakbin B, Br\u00fcck WM, Br\u00fcck TB. Molecular mechanisms of Shigella pathogenesis; recent advances. Int J Mol Sci. 2023;24(3):2448.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"735_CR47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12879-023-08096-0","volume":"23","author":"P Feuerstadt","year":"2023","unstructured":"Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the united states: a multifactorial challenge. BMC Infect Dis. 2023;23(1):132.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"735_CR48","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3390\/microorganisms8111640","volume":"8","author":"N Principi","year":"2020","unstructured":"Principi N, et al. Prevention of clostridium difficile infection and associated diarrhea: an unsolved problem. Microorganisms. 2020;8(11):1640.","journal-title":"Microorganisms"},{"issue":"1","key":"735_CR49","first-page":"27","volume":"10","author":"NNS Budayanti","year":"2022","unstructured":"Budayanti NNS, Aryana IGPS, Wedari NLPH. Clostridium diffi cile infection (CDI) by hypervirulent BI\/NAP1\/027 strain: a comprehensive review of toxigenicity, pathogenesis, risk factors, and preventative measures. Indonesian J Trop Infect Disease. 2022;10(1):27\u201341.","journal-title":"Indonesian J Trop Infect Disease"},{"issue":"12","key":"735_CR50","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/jac\/dkab231","volume":"76","author":"I Wickramage","year":"2021","unstructured":"Wickramage I, Spigaglia P, Sun X. Mechanisms of antibiotic resistance of clostridioides difficile. J Antimicrob Chemother. 2021;76(12):3077\u201390.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"735_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.rgmxen.2021.06.004","volume":"86","author":"R Contreras-Oma\u00f1a","year":"2021","unstructured":"Contreras-Oma\u00f1a R, Escorcia-Saucedo AE, Velarde-Ruiz JA, Velasco. Prevalence and impact of antimicrobial resistance in Gastrointestinal infections: A review. Revista De Gastroenterolog\u00eda De M\u00e9xico (English Edition). 2021;86(3):265\u201375.","journal-title":"Revista De Gastroenterolog\u00eda De M\u00e9xico (English Edition)"},{"issue":"4","key":"735_CR52","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1089\/mdr.2017.0323","volume":"24","author":"A Mart\u00ednez-Mel\u00e9ndez","year":"2018","unstructured":"Mart\u00ednez-Mel\u00e9ndez A, et al. Circulation of highly drug-resistant clostridium difficile ribotypes 027 and 001 in two tertiary-care hospitals in Mexico. Microb Drug Resist. 2018;24(4):386\u201392.","journal-title":"Microb Drug Resist"},{"issue":"1","key":"735_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31579\/2637-8914\/074","volume":"5","author":"M Pal","year":"2022","unstructured":"Pal M, et al. Staphylococcus aureus: A major pathogen of food poisoning: A rare research report. Nutr Food Process. 2022;5(1):1\u20133.","journal-title":"Nutr Food Process"},{"issue":"9","key":"735_CR54","doi-asserted-by":"publisher","first-page":"8182","DOI":"10.3390\/ijms24098182","volume":"24","author":"G Gherardi","year":"2023","unstructured":"Gherardi G. Staphylococcus aureus infection: pathogenesis and antimicrobial resistance. Int J Mol Sci. 2023;24(9):8182.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"735_CR55","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/toxins15080507","volume":"15","author":"D Lee","year":"2023","unstructured":"Lee D, et al. Expression of cholera toxin (CT) and the toxin Co-Regulated Pilus (TCP) by variants of ToxT in vibrio cholerae strains. Toxins. 2023;15(8):507.","journal-title":"Toxins"},{"issue":"12","key":"735_CR56","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.3390\/microorganisms12122504","volume":"12","author":"AA Asantewaa","year":"2024","unstructured":"Asantewaa AA, et al. Cholera outbreaks in Low- and Middle-Income countries in the last decade: A systematic review and Meta-Analysis. Microorganisms. 2024;12(12):2504.","journal-title":"Microorganisms"},{"key":"735_CR57","doi-asserted-by":"crossref","unstructured":"De R. Mobile genetic elements of vibrio cholerae and the evolution of its antimicrobial resistance. Front Trop Dis, 2021.;2:691604.","DOI":"10.3389\/fitd.2021.691604"},{"key":"735_CR58","doi-asserted-by":"crossref","unstructured":"Vashist A, et al. Molecular insights into genomic Islands and evolution of vibrio cholerae, in microbial genomic Islands in adaptation and pathogenicity. Springer; 2023;279\u2013324.","DOI":"10.1007\/978-981-19-9342-8_14"},{"issue":"1","key":"735_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13099-023-00537-0","volume":"15","author":"FT Jubyda","year":"2023","unstructured":"Jubyda FT, et al. Vibrio cholerae O1 associated with recent endemic cholera shows Temporal changes in serotype, genotype, and drug-resistance patterns in Bangladesh. Gut Pathogens. 2023;15(1):17.","journal-title":"Gut Pathogens"},{"issue":"1","key":"735_CR60","first-page":"1499869","volume":"2021","author":"SM Riahi","year":"2021","unstructured":"Riahi SM, Ahmadi E, Zeinali T. Global prevalence of yersinia Enterocolitica in cases of gastroenteritis: A systematic review and meta-analysis. Int J Microbiol. 2021;2021(1):1499869.","journal-title":"Int J Microbiol"},{"issue":"5","key":"735_CR61","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3390\/microorganisms13051133","volume":"13","author":"B Grygiel-G\u00f3rniak","year":"2025","unstructured":"Grygiel-G\u00f3rniak B. Current challenges in yersinia diagnosis and treatment. Microorganisms. 2025;13(5):1133.","journal-title":"Microorganisms"},{"issue":"12","key":"735_CR62","first-page":"e8442","volume":"21","author":"EFS Authority","year":"2023","unstructured":"European Food Safety Authority (EFSA); European Centre for Disease Prevention and Control (ECDC). The European Union One Health 2022 Zoonoses Report. EFSA J. 2023 Dec 12;21(12):e8442.","journal-title":"EFSA J"},{"issue":"15","key":"735_CR63","doi-asserted-by":"publisher","first-page":"11951","DOI":"10.3390\/ijms241511951","volume":"24","author":"C Huang","year":"2023","unstructured":"Huang C, Li W, Chen J. Stringent response factor DksA contributes to fatty acid degradation function to influence cell membrane stability and polymyxin B resistance of yersinia Enterocolitica. Int J Mol Sci. 2023;24(15):11951.","journal-title":"Int J Mol Sci"},{"key":"735_CR64","doi-asserted-by":"publisher","first-page":"664665","DOI":"10.3389\/fmicb.2021.664665","volume":"12","author":"PA Karlsson","year":"2021","unstructured":"Karlsson PA, et al. Molecular characterization of multidrug-resistant yersinia Enterocolitica from foodborne outbreaks in Sweden. Front Microbiol. 2021;12:664665.","journal-title":"Front Microbiol"},{"key":"735_CR65","doi-asserted-by":"publisher","first-page":"1339750","DOI":"10.3389\/fcimb.2024.1339750","volume":"14","author":"V Engelsberger","year":"2024","unstructured":"Engelsberger V, Gerhard M, Mej\u00edas-Luque R. Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk. Front Cell Infect Microbiol. 2024;14:1339750.","journal-title":"Front Cell Infect Microbiol"},{"key":"735_CR66","doi-asserted-by":"publisher","first-page":"568","DOI":"10.21614\/chirurgia.2023.v.118.i.6.p.568","volume":"118","author":"R Chivu","year":"2023","unstructured":"Chivu R, et al. Navigating through surgical implications of: an Up-to-Date comprehensive literature review. Chirurgia. 2023;118:568\u201383.","journal-title":"Chirurgia"},{"issue":"7","key":"735_CR67","doi-asserted-by":"publisher","first-page":"e24885","DOI":"10.1002\/jcla.24885","volume":"37","author":"Y Lin","year":"2023","unstructured":"Lin Y, et al. Antibiotic resistance in Helicobacter pylori: from potential biomolecular mechanisms to clinical practice. J Clin Lab Anal. 2023;37(7):e24885.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"735_CR68","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/tropicalmed8030163","volume":"8","author":"M Srisuphanunt","year":"2023","unstructured":"Srisuphanunt M, et al. Molecular mechanisms of antibiotic resistance and novel treatment strategies for Helicobacter pylori infections. Trop Med Infect Disease. 2023;8(3):163.","journal-title":"Trop Med Infect Disease"},{"key":"735_CR69","doi-asserted-by":"crossref","unstructured":"Pessoa RBG et al. Aeromonas and human health disorders: clinical approaches. Front Microbiol, 2022;13:868890","DOI":"10.3389\/fmicb.2022.868890"},{"key":"735_CR70","doi-asserted-by":"crossref","unstructured":"Cao B, Yan J, Santos JA, et al. Chap. 50 - Plesiomonas. Molecular medical microbiology (Third Edition), Y.-W. Tang. Academic; 2024;1027\u201342.","DOI":"10.1016\/B978-0-12-818619-0.00025-3"},{"issue":"4","key":"735_CR71","doi-asserted-by":"publisher","first-page":"e0301623","DOI":"10.1371\/journal.pone.0301623","volume":"19","author":"P Zhang","year":"2024","unstructured":"Zhang P, et al. Pathogenic characteristics of an aggregated diarrhea event caused by Plesiomonas shigelloides from stream. PLoS ONE. 2024;19(4):e0301623.","journal-title":"PLoS ONE"},{"issue":"5","key":"735_CR72","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/microorganisms12051031","volume":"12","author":"JM Janda","year":"2024","unstructured":"Janda JM, Duman M. Expanding the spectrum of diseases and disease associations caused by Edwardsiella Tarda and related species. Microorganisms. 2024;12(5):1031.","journal-title":"Microorganisms"},{"issue":"1","key":"735_CR73","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12879-025-10789-7","volume":"25","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, et al. A case of septic shock caused by drug-resistant Edwardsiella Tarda and literature review. BMC Infect Dis. 2025;25(1):393.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"735_CR74","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4161\/bact.1.1.14942","volume":"1","author":"MR Clokie","year":"2011","unstructured":"Clokie MR, et al. Phages in nature. Bacteriophage. 2011;1(1):31\u201345.","journal-title":"Bacteriophage"},{"issue":"3","key":"735_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.17352\/ijvsr.000126","volume":"8","author":"SB Gamachu","year":"2022","unstructured":"Gamachu SB, Debalo M. Review of bacteriophage and its applications. Int J Veterinary Sci Res. 2022;8(3):133\u201347.","journal-title":"Int J Veterinary Sci Res"},{"issue":"24","key":"735_CR76","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.3390\/ani13243826","volume":"13","author":"J Jord\u00e1","year":"2023","unstructured":"Jord\u00e1 J, et al. Phage-Based biosanitation strategies for minimizing persistent Salmonella and Campylobacter bacteria in poultry. Animals. 2023;13(24):3826.","journal-title":"Animals"},{"key":"735_CR77","doi-asserted-by":"publisher","unstructured":"Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2). https:\/\/doi.org\/10.1128\/cmr. 00066\u2013\u200918.","DOI":"10.1128\/cmr"},{"issue":"5","key":"735_CR78","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1039\/D2MA00980C","volume":"4","author":"HA Durr","year":"2023","unstructured":"Durr HA, Leipzig ND. Advancements in bacteriophage therapies and delivery for bacterial infection. Mater Adv. 2023;4(5):1249\u201357.","journal-title":"Mater Adv"},{"key":"735_CR79","doi-asserted-by":"publisher","first-page":"106199","DOI":"10.1016\/j.micpath.2023.106199","volume":"181","author":"Y Ali","year":"2023","unstructured":"Ali Y, et al. The current status of phage therapy and its advancement towards Establishing standard antimicrobials for combating multi drug-resistant bacterial pathogens. Microb Pathog. 2023;181:106199.","journal-title":"Microb Pathog"},{"issue":"9","key":"735_CR80","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrmicro.2016.94","volume":"14","author":"H-C Flemming","year":"2016","unstructured":"Flemming H-C, et al. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016;14(9):563\u201375.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"735_CR81","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/pharmaceutics16030374","volume":"16","author":"MM Vila","year":"2024","unstructured":"Vila MM, Balc\u00e3o LM, Balc\u00e3o VM. Phage delivery strategies for biocontrolling human, animal, and plant bacterial infections: state of the Art. Pharmaceutics. 2024;16(3):374.","journal-title":"Pharmaceutics"},{"issue":"10","key":"735_CR82","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/j.2042-7158.2011.01324.x","volume":"63","author":"EM Ryan","year":"2011","unstructured":"Ryan EM, et al. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol. 2011;63(10):1253\u201364.","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"735_CR83","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1089\/phage.2023.0024","volume":"4","author":"AM Al-Anany","year":"2023","unstructured":"Al-Anany AM, et al. Phage therapy in the management of urinary tract infections: a comprehensive systematic review. Phage. 2023;4(3):112\u201327.","journal-title":"Phage"},{"issue":"7","key":"735_CR84","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1128\/AAC.49.7.2874-2878.2005","volume":"49","author":"A Bruttin","year":"2005","unstructured":"Bruttin A, Br\u00fcssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother. 2005;49(7):2874\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"735_CR85","doi-asserted-by":"publisher","first-page":"692614","DOI":"10.3389\/fphar.2021.692614","volume":"12","author":"AV Johri","year":"2021","unstructured":"Johri AV, et al. Case report: chronic bacterial prostatitis treated with phage therapy after multiple failed antibiotic treatments. Front Pharmacol. 2021;12:692614.","journal-title":"Front Pharmacol"},{"key":"735_CR86","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/BF02932128","volume":"51","author":"P Leszczy\u0144ski","year":"2006","unstructured":"Leszczy\u0144ski P, et al. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker\u2014case report. Folia Microbiol. 2006;51:236\u20138.","journal-title":"Folia Microbiol"},{"issue":"1","key":"735_CR87","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12917-023-03724-y","volume":"19","author":"X Mao","year":"2023","unstructured":"Mao X, et al. Oral phage therapy with microencapsulated phage A221 against Escherichia coli infections in weaned piglets. BMC Vet Res. 2023;19(1):165.","journal-title":"BMC Vet Res"},{"issue":"2","key":"735_CR88","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1574-695X.2012.00977.x","volume":"65","author":"EM Ryan","year":"2012","unstructured":"Ryan EM, et al. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol. 2012;65(2):395\u20138.","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"12","key":"735_CR89","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3390\/v12121470","volume":"12","author":"IH Korf","year":"2020","unstructured":"Korf IH, et al. In vitro evaluation of a phage cocktail controlling infections with Escherichia coli. Viruses. 2020;12(12):1470.","journal-title":"Viruses"},{"issue":"4","key":"735_CR90","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/microorganisms7040094","volume":"7","author":"P Costa","year":"2019","unstructured":"Costa P, et al. Efficiency of single phage suspensions and phage cocktail in the inactivation of Escherichia coli and Salmonella typhimurium: an in vitro preliminary study. Microorganisms. 2019;7(4):94.","journal-title":"Microorganisms"},{"key":"735_CR91","doi-asserted-by":"publisher","first-page":"1479700","DOI":"10.3389\/fmicb.2024.1479700","volume":"15","author":"N Battistelli","year":"2024","unstructured":"Battistelli N, et al. In vitro characterization and genome sequencing of two novel lytic phages against Salmonella infantis isolated from poultry feces. Front Microbiol. 2024;15:1479700.","journal-title":"Front Microbiol"},{"key":"735_CR92","doi-asserted-by":"publisher","first-page":"664810","DOI":"10.3389\/fmicb.2021.664810","volume":"12","author":"Y Shang","year":"2021","unstructured":"Shang Y, et al. Isolation and characterization of a novel Salmonella phage vB_SalP_TR2. Front Microbiol. 2021;12:664810.","journal-title":"Front Microbiol"},{"key":"735_CR93","doi-asserted-by":"publisher","first-page":"111000","DOI":"10.1016\/j.foodcont.2024.111000","volume":"169","author":"W Pelyuntha","year":"2025","unstructured":"Pelyuntha W, et al. Effect of novel phage cocktail on Salmonella recovered from broiler sources and its anti-biofilm effect on food contact surface model. Food Control. 2025;169:111000.","journal-title":"Food Control"},{"issue":"2","key":"735_CR94","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/antibiotics11020228","volume":"11","author":"SM Steffan","year":"2022","unstructured":"Steffan SM, et al. Campylobacter bacteriophage cocktail design based on an advanced selection scheme. Antibiotics. 2022;11(2):228.","journal-title":"Antibiotics"},{"key":"735_CR95","doi-asserted-by":"publisher","first-page":"110975","DOI":"10.1016\/j.ijfoodmicro.2024.110975","volume":"427","author":"K Xiao","year":"2025","unstructured":"Xiao K, et al. Application of a novel phage vB_CjeM_WX1 to control Campylobacter jejuni in foods. Int J Food Microbiol. 2025;427:110975.","journal-title":"Int J Food Microbiol"},{"issue":"4","key":"735_CR96","doi-asserted-by":"publisher","first-page":"103548","DOI":"10.1016\/j.psj.2024.103548","volume":"103","author":"X Zhang","year":"2024","unstructured":"Zhang X, et al. A broad host phage, CP6, for combating multidrug-resistant Campylobacter prevalent in poultry meat. Poult Sci. 2024;103(4):103548.","journal-title":"Poult Sci"},{"issue":"2","key":"735_CR97","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/zoonoticdis2020007","volume":"2","author":"A-R Al-Mohammadi","year":"2022","unstructured":"Al-Mohammadi A-R, et al. Isolation and characterization of lytic bacteriophages specific for Campylobacter jejuni and Campylobacter coli. Zoonotic Dis. 2022;2(2):59\u201372.","journal-title":"Zoonotic Dis"},{"issue":"1","key":"735_CR98","doi-asserted-by":"publisher","first-page":"19313","DOI":"10.1038\/s41598-021-98910-z","volume":"11","author":"B Mallick","year":"2021","unstructured":"Mallick B, Mondal P, Dutta M. Morphological, biological, and genomic characterization of a newly isolated lytic phage Sfk20 infecting Shigella flexneri, Shigella sonnei, and Shigella dysenteriae1. Sci Rep. 2021;11(1):19313.","journal-title":"Sci Rep"},{"issue":"10","key":"735_CR99","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3390\/microorganisms9102105","volume":"9","author":"S-H Kim","year":"2021","unstructured":"Kim S-H, Adeyemi DE, Park M-K. Characterization of a new and efficient polyvalent phage infecting E. coli O157: H7, Salmonella spp., and Shigella sonnei. Microorganisms. 2021;9(10):2105.","journal-title":"Microorganisms"},{"key":"735_CR100","doi-asserted-by":"publisher","first-page":"104641","DOI":"10.1016\/j.fm.2024.104641","volume":"125","author":"J Choi","year":"2025","unstructured":"Choi J, Park S, Chang Y. Development and application of a bacteriophage cocktail for Shigella flexneri biofilm Inhibition on the stainless steel surface. Food Microbiol. 2025;125:104641.","journal-title":"Food Microbiol"},{"issue":"1","key":"735_CR101","doi-asserted-by":"publisher","first-page":"e02295","DOI":"10.1128\/spectrum.02295-21","volume":"10","author":"M Whittle","year":"2022","unstructured":"Whittle M, et al. A novel bacteriophage with broad host range against clostridioides difficile ribotype 078 supports SlpA as the likely phage receptor. Microbiol Spectr. 2022;10(1):e02295\u201321.","journal-title":"Microbiol Spectr"},{"issue":"2","key":"735_CR102","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1128\/AAC.01774-15","volume":"60","author":"JY Nale","year":"2016","unstructured":"Nale JY, et al. Bacteriophage combinations significantly reduce clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother. 2016;60(2):968\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"735_CR103","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.anaerobe.2010.08.006","volume":"16","author":"E Meader","year":"2010","unstructured":"Meader E, et al. Bacteriophage treatment significantly reduces viable clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe. 2010;16(6):549\u201354.","journal-title":"Anaerobe"},{"key":"735_CR104","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.anaerobe.2013.05.001","volume":"22","author":"E Meader","year":"2013","unstructured":"Meader E, et al. Evaluation of bacteriophage therapy to control clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe. 2013;22:25\u201330.","journal-title":"Anaerobe"},{"key":"735_CR105","doi-asserted-by":"crossref","unstructured":"Gwak KM et al. Isolation and characterization of a lytic and highly specific phage against yersinia Enterocolitica as a novel biocontrol agent. 2018.","DOI":"10.4014\/jmb.1808.08001"},{"issue":"8","key":"735_CR106","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2217\/fvl.13.58","volume":"8","author":"ME Abdel-Haliem","year":"2013","unstructured":"Abdel-Haliem ME, Askora A. Isolation and characterization of bacteriophages of Helicobacter pylori isolated from Egypt. Future Virol. 2013;8(8):821\u20136.","journal-title":"Future Virol"},{"issue":"10","key":"735_CR107","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1128\/AEM.03530-12","volume":"79","author":"J Uchiyama","year":"2013","unstructured":"Uchiyama J, et al. Characterization of Helicobacter pylori bacteriophage KHP30. Appl Environ Microbiol. 2013;79(10):3176\u201384.","journal-title":"Appl Environ Microbiol"},{"issue":"8","key":"735_CR108","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/microorganisms8081214","volume":"8","author":"P Cuomo","year":"2020","unstructured":"Cuomo P, et al. An innovative approach to control H. pylori-induced persistent inflammation and colonization. Microorganisms. 2020;8(8):1214.","journal-title":"Microorganisms"},{"key":"735_CR109","doi-asserted-by":"publisher","first-page":"609955","DOI":"10.3389\/fmicb.2020.609955","volume":"11","author":"JY Nale","year":"2021","unstructured":"Nale JY, et al. An optimized bacteriophage cocktail can effectively control Salmonella in vitro and in galleria Mellonella. Front Microbiol. 2021;11:609955.","journal-title":"Front Microbiol"},{"issue":"1","key":"735_CR110","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12941-024-00678-3","volume":"23","author":"RA Youssef","year":"2024","unstructured":"Youssef RA, et al. Genomic characterization, in vitro, and preclinical evaluation of two microencapsulated lytic phages VB_ST_E15 and VB_ST_SPNIS2 against clinical multidrug-resistant Salmonella serovars. Ann Clin Microbiol Antimicrob. 2024;23(1):17.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"735_CR111","doi-asserted-by":"publisher","first-page":"698962","DOI":"10.3389\/fmicb.2021.698962","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, et al. Molecular characteristics of novel phage vB_ShiP-A7 infecting multidrug-resistant Shigella flexneri and Escherichia coli, and its bactericidal effect in vitro and in vivo. Front Microbiol. 2021;12:698962.","journal-title":"Front Microbiol"},{"issue":"6","key":"735_CR112","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/antibiotics12061046","volume":"12","author":"N Chaudhary","year":"2023","unstructured":"Chaudhary N, et al. Vibrio phage VMJ710 can prevent and treat disease caused by pathogenic MDR V. cholerae O1 in an infant mouse model. Antibiotics. 2023;12(6):1046.","journal-title":"Antibiotics"},{"key":"735_CR113","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fmicb.2020.00351","volume":"11","author":"Y Xue","year":"2020","unstructured":"Xue Y, et al. The yersinia phage X1 administered orally efficiently protects a murine chronic enteritis model against yersinia Enterocolitica infection. Front Microbiol. 2020;11:351.","journal-title":"Front Microbiol"},{"issue":"1","key":"735_CR114","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1146\/annurev-virology-100114-054915","volume":"2","author":"D Vandenheuvel","year":"2015","unstructured":"Vandenheuvel D, Lavigne R, Br\u00fcssow H. Bacteriophage therapy: advances in formulation strategies and human clinical trials. Annual Rev Virol. 2015;2(1):599\u2013618.","journal-title":"Annual Rev Virol"},{"key":"735_CR115","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","volume":"4","author":"SA Sarker","year":"2016","unstructured":"Sarker SA, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: A randomized trial in children from Bangladesh. eBioMedicine. 2016;4:124\u201337.","journal-title":"eBioMedicine"},{"issue":"9","key":"735_CR116","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/antibiotics13090858","volume":"13","author":"WH Chen","year":"2024","unstructured":"Chen WH, et al. Safety and tolerability of shigactive\u2122, a Shigella spp. Targeting bacteriophage preparation, in a phase 1 randomized, Double-Blind, controlled clinical trial. Antibiotics. 2024;13(9):858.","journal-title":"Antibiotics"},{"key":"735_CR117","doi-asserted-by":"publisher","first-page":"594868","DOI":"10.3389\/fmicb.2020.594868","volume":"11","author":"N \u00c1cs","year":"2020","unstructured":"\u00c1cs N, Gambino M, Br\u00f8ndsted L. Bacteriophage enumeration and detection methods. Front Microbiol. 2020;11:594868.","journal-title":"Front Microbiol"},{"issue":"7","key":"735_CR118","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1128\/AEM.67.7.2895-2902.2001","volume":"67","author":"J Koo","year":"2001","unstructured":"Koo J, Marshall DL, DePaola A. Antacid increases survival of vibrio vulnificus and vibrio vulnificus phage in a Gastrointestinal model. Appl Environ Microbiol. 2001;67(7):2895\u2013902.","journal-title":"Appl Environ Microbiol"},{"issue":"5","key":"735_CR119","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1099\/00221287-133-5-1127","volume":"133","author":"HW Smith","year":"1987","unstructured":"Smith HW, Huggins MB, Shaw KM. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. Microbiology. 1987;133(5):1127\u201335.","journal-title":"Microbiology"},{"issue":"3","key":"735_CR120","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1263\/jbb.100.280","volume":"100","author":"Y Tanji","year":"2005","unstructured":"Tanji Y, et al. Therapeutic use of phage cocktail for controlling Escherichia coli O157: H7 in Gastrointestinal tract of mice. J Biosci Bioeng. 2005;100(3):280\u20137.","journal-title":"J Biosci Bioeng"},{"key":"735_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13567-021-00991-1","volume":"52","author":"H Yin","year":"2021","unstructured":"Yin H, et al. Microencapsulated phages show prolonged stability in Gastrointestinal environments and high therapeutic efficiency to treat Escherichia coli O157: H7 infection. Vet Res. 2021;52:1\u201313.","journal-title":"Vet Res"},{"key":"735_CR122","doi-asserted-by":"crossref","unstructured":"Clokie MRJ, Kropinski. and R. e.e.h.i.l.g.v.r.e. Lavigne, Bacteriophages Methods and Protocols, Volume 3. 1st ed. 2018;2018.","DOI":"10.1007\/978-1-4939-7343-9"},{"key":"735_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-394621-8.00017-0","volume":"82","author":"H-W Ackermann","year":"2012","unstructured":"Ackermann H-W. Bacteriophage electron microscopy. Adv Virus Res. 2012;82:1\u201332.","journal-title":"Adv Virus Res"},{"issue":"1\u20132","key":"735_CR124","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0166-0934(99)00167-6","volume":"85","author":"CP Brussaard","year":"2000","unstructured":"Brussaard CP, Marie D, Bratbak G. Flow cytometric detection of viruses. J Virol Methods. 2000;85(1\u20132):175\u201382.","journal-title":"J Virol Methods"},{"issue":"2","key":"735_CR125","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4161\/bact.1.2.15456","volume":"1","author":"B Anderson","year":"2011","unstructured":"Anderson B, et al. Enumeration of bacteriophage particles: comparative analysis of the traditional plaque assay and real-time QPCR-and nanosight-based assays. Bacteriophage. 2011;1(2):86\u201393.","journal-title":"Bacteriophage"},{"issue":"1","key":"735_CR126","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1574-6968.2011.02342.x","volume":"322","author":"D Guti\u00e9rrez","year":"2011","unstructured":"Guti\u00e9rrez D, et al. Typing of bacteriophages by randomly amplified polymorphic DNA (RAPD)-PCR to assess genetic diversity. FEMS Microbiol Lett. 2011;322(1):90\u20137.","journal-title":"FEMS Microbiol Lett"},{"key":"735_CR127","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jviromet.2018.05.007","volume":"259","author":"NM Morella","year":"2018","unstructured":"Morella NM, et al. Rapid quantification of bacteriophages and their bacterial hosts in vitro and in vivo using droplet digital PCR. J Virol Methods. 2018;259:18\u201324.","journal-title":"J Virol Methods"},{"key":"735_CR128","doi-asserted-by":"publisher","first-page":"113354","DOI":"10.1016\/j.ab.2019.113354","volume":"582","author":"T Wang","year":"2019","unstructured":"Wang T, et al. Mass spectrometry enumeration of filamentous M13 bacteriophage. Anal Biochem. 2019;582:113354.","journal-title":"Anal Biochem"},{"issue":"3","key":"735_CR129","doi-asserted-by":"publisher","first-page":"190","DOI":"10.4161\/bact.22111","volume":"2","author":"J Klumpp","year":"2012","unstructured":"Klumpp J, Fouts DE, Sozhamannan S. Next generation sequencing technologies and the changing landscape of phage genomics. Bacteriophage. 2012;2(3):190\u20139.","journal-title":"Bacteriophage"},{"issue":"16","key":"735_CR130","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1016\/j.cell.2022.07.003","volume":"185","author":"S Federici","year":"2022","unstructured":"Federici S, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell. 2022;185(16):2879\u2013e289824.","journal-title":"Cell"},{"issue":"14","key":"735_CR131","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1128\/AEM.00812-15","volume":"81","author":"J Colom","year":"2015","unstructured":"Colom J, et al. Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl Environ Microbiol. 2015;81(14):4841\u20139.","journal-title":"Appl Environ Microbiol"},{"issue":"10","key":"735_CR132","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.3390\/microorganisms11102389","volume":"11","author":"SB Dlamini","year":"2023","unstructured":"Dlamini SB, et al. Efficacy of different encapsulation techniques on the viability and stability of diverse phage under simulated gastric conditions. Microorganisms. 2023;11(10):2389.","journal-title":"Microorganisms"},{"issue":"15","key":"735_CR133","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1128\/AEM.00246-08","volume":"74","author":"Y Ma","year":"2008","unstructured":"Ma Y, et al. Microencapsulation of bacteriophage Felix O1 into chitosan-alginate microspheres for oral delivery. Appl Environ Microbiol. 2008;74(15):4799\u2013805.","journal-title":"Appl Environ Microbiol"},{"issue":"7","key":"735_CR134","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.4315\/0362-028X-73.7.1304","volume":"73","author":"K Stanford","year":"2010","unstructured":"Stanford K, et al. Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157: H7 in feedlot cattle. J Food Prot. 2010;73(7):1304\u201312.","journal-title":"J Food Prot"},{"key":"735_CR135","doi-asserted-by":"publisher","first-page":"110004","DOI":"10.1016\/j.foodres.2020.110004","volume":"140","author":"J Li","year":"2021","unstructured":"Li J, et al. Characterization of a novel siphoviridae Salmonella bacteriophage T156 and its microencapsulation application in food matrix. Food Res Int. 2021;140:110004.","journal-title":"Food Res Int"},{"key":"735_CR136","doi-asserted-by":"publisher","first-page":"1101872","DOI":"10.3389\/fvets.2022.1101872","volume":"9","author":"B Zhang","year":"2023","unstructured":"Zhang B, et al. Microencapsulated phage composites with increased Gastrointestinal stability for the oral treatment of Salmonella colonization in chicken. Front Veterinary Sci. 2023;9:1101872.","journal-title":"Front Veterinary Sci"},{"key":"735_CR137","doi-asserted-by":"crossref","unstructured":"D\u0105browska K, G\u00f3rski A, Abedon ST. Bacteriophage pharmacology and immunology. Bacteriophages: Biology, Technology, Therapy, 2021: pp. 295\u2013339.","DOI":"10.1007\/978-3-319-41986-2_9"},{"key":"735_CR138","doi-asserted-by":"publisher","first-page":"635597","DOI":"10.3389\/fcimb.2021.635597","volume":"11","author":"IM Abd-Allah","year":"2021","unstructured":"Abd-Allah IM, et al. Rekindling of a masterful precedent; bacteriophage: reappraisal and future pursuits. Front Cell Infect Microbiol. 2021;11:635597.","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"735_CR139","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cmi.2023.01.021","volume":"29","author":"SC Nang","year":"2023","unstructured":"Nang SC, et al. Pharmacokinetics\/pharmacodynamics of phage therapy: a major hurdle to clinical translation. Clin Microbiol Infect. 2023;29(6):702\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"735_CR140","doi-asserted-by":"publisher","first-page":"00012","DOI":"10.1128\/mmbr","volume":"83","author":"K D\u0105browska","year":"2019","unstructured":"D\u0105browska K, Abedon ST. Pharmacologically aware phage therapy: pharmacodynamic and Pharmacokinetic Obstacles to phage antibacterial action in animal and human bodies. Microbiol Mol Biol Rev. 2019;83(4):00012\u201319. https:\/\/doi.org\/10.1128\/mmbr","journal-title":"Microbiol Mol Biol Rev"},{"issue":"6","key":"735_CR141","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/microorganisms12061163","volume":"12","author":"B Reyneke","year":"2024","unstructured":"Reyneke B, et al. Benefits and challenges of applying bacteriophage biocontrol in the consumer water cycle. Microorganisms. 2024;12(6):1163.","journal-title":"Microorganisms"},{"issue":"6","key":"735_CR142","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/pathogens13060522","volume":"13","author":"P Bozidis","year":"2024","unstructured":"Bozidis P, et al. Does phage therapy need a pan-phage? Pathogens. 2024;13(6):522.","journal-title":"Pathogens"},{"issue":"10","key":"735_CR143","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s13205-024-04101-8","volume":"14","author":"A Kapoor","year":"2024","unstructured":"Kapoor A, et al. Phage therapy: A novel approach against multidrug-resistant pathogens. 3 Biotech. 2024;14(10):256.","journal-title":"3 Biotech"},{"key":"735_CR144","doi-asserted-by":"crossref","unstructured":"Costa P et al. A Game of Resistance: War Between Bacteria and Phages and How Phage Cocktails can be the Solution. Virology, 2024: p. 110209.","DOI":"10.1016\/j.virol.2024.110209"},{"issue":"4","key":"735_CR145","doi-asserted-by":"publisher","first-page":"167","DOI":"10.12793\/tcp.2023.31.e17","volume":"31","author":"D Chae","year":"2023","unstructured":"Chae D. Phage-host-immune system dynamics in bacteriophage therapy: basic principles and mathematical models. Translational Clin Pharmacol. 2023;31(4):167.","journal-title":"Translational Clin Pharmacol"},{"issue":"5","key":"735_CR146","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.cmi.2023.01.018","volume":"29","author":"C Cervera","year":"2023","unstructured":"Cervera C. Current landscape on phage therapy in infections: time to leave it behind for good? Clin Microbiol Infect. 2023;29(5):565\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"6566","key":"735_CR147","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1126\/science.abb1083","volume":"374","author":"FA Hussain","year":"2021","unstructured":"Hussain FA, et al. Rapid evolutionary turnover of mobile genetic elements drives bacterial resistance to phages. Science. 2021;374(6566):488\u201392.","journal-title":"Science"},{"issue":"2","key":"735_CR148","first-page":"245","volume":"12","author":"ST Abedon","year":"2023","unstructured":"Abedon ST, Ecology, Evolutionary Biology of Hindering Phage Therapy. The phage tolerance vs. Phage Resist Bacterial Biofilms Antibiot. 2023;12(2):245.","journal-title":"Phage Resist Bacterial Biofilms Antibiot"},{"key":"735_CR149","doi-asserted-by":"publisher","first-page":"101201","DOI":"10.1016\/j.coviro.2022.101201","volume":"53","author":"C Torres-Barcel\u00f3","year":"2022","unstructured":"Torres-Barcel\u00f3 C, Turner PE, Buckling A. Mitigation of evolved bacterial resistance to phage therapy. Curr Opin Virol. 2022;53:101201.","journal-title":"Curr Opin Virol"},{"key":"735_CR150","doi-asserted-by":"publisher","first-page":"e03497","DOI":"10.7554\/eLife.03497","volume":"3","author":"KD Seed","year":"2014","unstructured":"Seed KD, et al. Evolutionary consequences of intra-patient phage predation on microbial populations. Elife. 2014;3:e03497.","journal-title":"Elife"},{"issue":"8","key":"735_CR151","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1099\/00221287-129-8-2659","volume":"129","author":"HW Smith","year":"1983","unstructured":"Smith HW, Huggins M. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. Microbiology. 1983;129(8):2659\u201375.","journal-title":"Microbiology"},{"key":"735_CR152","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fcimb.2012.00011","volume":"2","author":"MCH S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen MCH, et al. Phase variable expression of capsular polysaccharide modifications allows Campylobacter jejuni to avoid bacteriophage infection in chickens. Front Cell Infect Microbiol. 2012;2:11.","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"735_CR153","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3390\/ph16101467","volume":"16","author":"KM Chung","year":"2023","unstructured":"Chung KM, Liau XL, Tang SS. Bacteriophages and their host range in multidrug-resistant bacterial disease treatment. Pharmaceuticals. 2023;16(10):1467.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"735_CR154","doi-asserted-by":"publisher","first-page":"e3002119","DOI":"10.1371\/journal.pbio.3002119","volume":"21","author":"A Petrovic Fabijan","year":"2023","unstructured":"Petrovic Fabijan A, et al. Translating phage therapy into the clinic: recent accomplishments but continuing challenges. PLoS Biol. 2023;21(5):e3002119.","journal-title":"PLoS Biol"},{"issue":"24","key":"735_CR155","doi-asserted-by":"publisher","first-page":"13316","DOI":"10.3390\/ijms252413316","volume":"25","author":"X Xu","year":"2024","unstructured":"Xu X, Gu P. Overview of phage defense systems in bacteria and their applications. Int J Mol Sci. 2024;25(24):13316.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"735_CR156","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3390\/pharmaceutics14020427","volume":"14","author":"S Liu","year":"2022","unstructured":"Liu S, et al. Phages against pathogenic bacterial biofilms and Biofilm-Based infections: A review. Pharmaceutics. 2022;14(2):427.","journal-title":"Pharmaceutics"},{"issue":"7","key":"735_CR157","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/v13071389","volume":"13","author":"KRH Biggs","year":"2021","unstructured":"Biggs KRH, et al. Ecological approach to Understanding superinfection Inhibition in bacteriophage. Viruses. 2021;13(7):1389.","journal-title":"Viruses"},{"issue":"1","key":"735_CR158","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s42003-020-01412-3","volume":"3","author":"K Shi","year":"2020","unstructured":"Shi K, et al. Structural basis of superinfection exclusion by bacteriophage T4 spackle. Commun Biology. 2020;3(1):691.","journal-title":"Commun Biology"},{"issue":"23","key":"735_CR159","doi-asserted-by":"publisher","first-page":"01630","DOI":"10.1128\/jvi","volume":"94","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Covalent modifications of the bacteriophage genome confer a degree of resistance to bacterial CRISPR systems. J Virol. 2020;94(23):01630\u201320. https:\/\/doi.org\/10.1128\/jvi","journal-title":"J Virol"},{"key":"735_CR160","doi-asserted-by":"crossref","unstructured":"Smirnov S et al. Fluorescence microscopy study of the effect of Esp1396I restriction-modification system proteins concentrations on protection against lambda phage. in Journal of Physics: Conference Series. 2018. IOP Publishing.","DOI":"10.1088\/1742-6596\/1135\/1\/012016"},{"issue":"5","key":"735_CR161","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41564-020-0691-3","volume":"5","author":"AL Borges","year":"2020","unstructured":"Borges AL, et al. Bacterial alginate regulators and phage homologs repress CRISPR\u2013Cas immunity. Nat Microbiol. 2020;5(5):679\u201387.","journal-title":"Nat Microbiol"},{"issue":"1","key":"735_CR162","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev-virology-011620-040628","volume":"7","author":"A Lopatina","year":"2020","unstructured":"Lopatina A, Tal N, Sorek R. Abortive infection: bacterial suicide as an antiviral immune strategy. Annual Rev Virol. 2020;7(1):371\u201384.","journal-title":"Annual Rev Virol"},{"key":"735_CR163","doi-asserted-by":"crossref","unstructured":"Feyereisen M et al. Identification of a prophage-encoded abortive infection system in Levilactobacillus brevis. 2020.","DOI":"10.4014\/mbl.2002.02017"},{"key":"735_CR164","doi-asserted-by":"publisher","first-page":"103647","DOI":"10.1016\/j.fm.2020.103647","volume":"94","author":"PK Montso","year":"2021","unstructured":"Montso PK, Mlambo V, Ateba CN. Efficacy of novel phages for control of multi-drug resistant Escherichia coli O177 on artificially contaminated beef and their potential to disrupt biofilm formation. Food Microbiol. 2021;94:103647.","journal-title":"Food Microbiol"},{"key":"735_CR165","doi-asserted-by":"publisher","first-page":"198496","DOI":"10.1016\/j.virusres.2021.198496","volume":"302","author":"S Malik","year":"2021","unstructured":"Malik S, Nehra K, Rana J. Bacteriophage cocktail and phage antibiotic synergism as promising alternatives to conventional antibiotics for the control of multi-drug-resistant uropathogenic Escherichia coli. Virus Res. 2021;302:198496.","journal-title":"Virus Res"},{"issue":"5","key":"735_CR166","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/jam.14026","volume":"125","author":"A Maszewska","year":"2018","unstructured":"Maszewska A, et al. Use of polyvalent bacteriophages to combat biofilm of proteus mirabilis causing catheter-associated urinary tract infections. J Appl Microbiol. 2018;125(5):1253\u201365.","journal-title":"J Appl Microbiol"},{"key":"735_CR167","doi-asserted-by":"publisher","first-page":"100038","DOI":"10.1016\/j.bioflm.2020.100038","volume":"2","author":"EM Townsend","year":"2020","unstructured":"Townsend EM, Moat J, Jameson E. CAUTI\u2019s next top model\u2013Model dependent Klebsiella biofilm Inhibition by bacteriophages and antimicrobials. Biofilm. 2020;2:100038.","journal-title":"Biofilm"},{"issue":"1","key":"735_CR168","doi-asserted-by":"publisher","first-page":"e0168615","DOI":"10.1371\/journal.pone.0168615","volume":"12","author":"WN Chaudhry","year":"2017","unstructured":"Chaudhry WN, et al. Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS ONE. 2017;12(1):e0168615.","journal-title":"PLoS ONE"},{"key":"735_CR169","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fmicb.2018.00127","volume":"9","author":"D Kumaran","year":"2018","unstructured":"Kumaran D, et al. Does treatment order matter? Investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms. Front Microbiol. 2018;9:127.","journal-title":"Front Microbiol"},{"key":"735_CR170","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.copbio.2019.11.013","volume":"61","author":"P Huss","year":"2020","unstructured":"Huss P, Raman S. Engineered bacteriophages as programmable biocontrol agents. Curr Opin Biotechnol. 2020;61:116\u201321.","journal-title":"Curr Opin Biotechnol"},{"key":"735_CR171","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s12250-020-00233-2","volume":"35","author":"M Li","year":"2020","unstructured":"Li M, et al. Recombination of T4-like phages and its activity against pathogenic Escherichia coli in planktonic and biofilm forms. Virol Sin. 2020;35:651\u201361.","journal-title":"Virol Sin"},{"issue":"27","key":"735_CR172","doi-asserted-by":"publisher","first-page":"11197","DOI":"10.1073\/pnas.0704624104","volume":"104","author":"TK Lu","year":"2007","unstructured":"Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci. 2007;104(27):11197\u2013202.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"735_CR173","doi-asserted-by":"publisher","first-page":"e00341","DOI":"10.1128\/AEM.00341-17","volume":"83","author":"Y Born","year":"2017","unstructured":"Born Y, et al. Engineering of bacteriophages Y2:: dpoL1-C and Y2:: LuxAB for efficient control and rapid detection of the fire blight pathogen, erwinia Amylovora. Appl Environ Microbiol. 2017;83(12):e00341\u201317.","journal-title":"Appl Environ Microbiol"},{"key":"735_CR174","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.copbio.2021.02.002","volume":"68","author":"J Azeredo","year":"2021","unstructured":"Azeredo J, Garcia P, Drulis-Kawa Z. Targeting biofilms using phages and their enzymes. Curr Opin Biotechnol. 2021;68:251\u201361.","journal-title":"Curr Opin Biotechnol"},{"key":"735_CR175","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3389\/fmicb.2019.01251","volume":"10","author":"R V\u00e1zquez","year":"2019","unstructured":"V\u00e1zquez R, Garc\u00eda P. Synergy between two chimeric lysins to kill Streptococcus pneumoniae. Front Microbiol. 2019;10:1251.","journal-title":"Front Microbiol"},{"issue":"11","key":"735_CR176","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2217\/fmb-2018-0077","volume":"13","author":"P Letrado","year":"2018","unstructured":"Letrado P, et al. Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant Pneumococcus. Future Microbiol. 2018;13(11):1215\u201323.","journal-title":"Future Microbiol"},{"issue":"20","key":"735_CR177","doi-asserted-by":"publisher","first-page":"e00980","DOI":"10.1128\/AEM.00980-21","volume":"87","author":"E Stachler","year":"2021","unstructured":"Stachler E, Kull A, Julian TR. Bacteriophage treatment before chemical disinfection can enhance removal of plastic-surface-associated Pseudomonas aeruginosa. Appl Environ Microbiol. 2021;87(20):e00980\u201321.","journal-title":"Appl Environ Microbiol"},{"key":"735_CR178","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcis.2018.07.107","volume":"532","author":"S Bone","year":"2018","unstructured":"Bone S, et al. Physisorption and chemisorption of T4 bacteriophages on amino functionalized silica particles. J Colloid Interface Sci. 2018;532:68\u201376.","journal-title":"J Colloid Interface Sci"},{"issue":"1","key":"735_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44259-025-00117-z","volume":"3","author":"BW Cook","year":"2025","unstructured":"Cook BW, Hynes AP. Re-evaluating what makes a phage unsuitable for therapy. Npj Antimicrobials Resist. 2025;3(1):1\u20135.","journal-title":"Npj Antimicrobials Resist"},{"issue":"3","key":"735_CR180","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bcp.13833","volume":"85","author":"J Borysowski","year":"2019","unstructured":"Borysowski J, Ehni HJ, G\u00f3rski A. Ethics codes and use of new and innovative drugs. Br J Clin Pharmacol. 2019;85(3):501\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"735_CR181","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/v11040352","volume":"11","author":"A Fauconnier","year":"2019","unstructured":"Fauconnier A. Phage therapy regulation: from night to dawn. Viruses. 2019;11(4):352.","journal-title":"Viruses"},{"key":"735_CR182","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3389\/fmicb.2020.01056","volume":"11","author":"M \u017baczek","year":"2020","unstructured":"\u017baczek M, et al. Phage therapy in Poland\u2013a centennial journey to the first ethically approved treatment facility in Europe. Front Microbiol. 2020;11:1056.","journal-title":"Front Microbiol"},{"key":"735_CR183","doi-asserted-by":"publisher","first-page":"701898","DOI":"10.3389\/fmicb.2021.701898","volume":"12","author":"P Knezevic","year":"2021","unstructured":"Knezevic P, et al. Advances in phage therapy: present challenges and future perspectives. Front Microbiol. 2021;12:701898.","journal-title":"Front Microbiol"},{"key":"735_CR184","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.copbio.2020.12.018","volume":"68","author":"RC Lin","year":"2021","unstructured":"Lin RC, et al. Phage biobank: present challenges and future perspectives. Curr Opin Biotechnol. 2021;68:221\u201330.","journal-title":"Curr Opin Biotechnol"},{"issue":"3","key":"735_CR185","doi-asserted-by":"publisher","first-page":"e02071","DOI":"10.1128\/aac.02071-21","volume":"66","author":"GA Suh","year":"2022","unstructured":"Suh GA, et al. Considerations for the use of phage therapy in clinical practice. Antimicrob Agents Chemother. 2022;66(3):e02071\u201321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"735_CR186","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","volume":"45","author":"A Sulakvelidze","year":"2001","unstructured":"Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649\u201359.","journal-title":"Antimicrob Agents Chemother"},{"key":"735_CR187","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-394438-2.00003-7","volume":"83","author":"R Mi\u0119dzybrodzki","year":"2012","unstructured":"Mi\u0119dzybrodzki R, et al. Clinical aspects of phage therapy. Adv Virus Res. 2012;83:73\u2013121.","journal-title":"Adv Virus Res"},{"issue":"6","key":"735_CR188","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/v10060288","volume":"10","author":"A G\u00f3rski","year":"2018","unstructured":"G\u00f3rski A, et al. Phage therapy: what have we learned? Viruses. 2018;10(6):288.","journal-title":"Viruses"},{"issue":"1","key":"735_CR189","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/med.21593","volume":"40","author":"A G\u00f3rski","year":"2020","unstructured":"G\u00f3rski A, et al. Phage therapy: current status and perspectives. Med Res Rev. 2020;40(1):459\u201363.","journal-title":"Med Res Rev"},{"key":"735_CR190","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s11095-010-0313-5","volume":"28","author":"J-P Pirnay","year":"2011","unstructured":"Pirnay J-P, et al. The phage therapy paradigm: pr\u00eat-\u00e0-porter or sur-mesure? Pharm Res. 2011;28:934\u20137.","journal-title":"Pharm Res"},{"issue":"2","key":"735_CR191","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/v10020064","volume":"10","author":"J-P Pirnay","year":"2018","unstructured":"Pirnay J-P, et al. The magistral phage. Viruses. 2018;10(2):64.","journal-title":"Viruses"},{"key":"735_CR192","doi-asserted-by":"crossref","unstructured":"Aslam S et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat Multidrug-Resistant bacterial infections at a single center in the united States. Open Forum Infect Dis, 2020;7(9).","DOI":"10.1093\/ofid\/ofaa389"},{"issue":"2","key":"735_CR193","doi-asserted-by":"publisher","first-page":"243","DOI":"10.22146\/farmaseutik.v17i2.60237","volume":"17","author":"F Aziza","year":"2021","unstructured":"Aziza F. Comparison review of two regulatory agencies regulation: therapeutic goods administration (TGA) and the European medicine agency (EMA) in relation to good manufacturing practice (GMP) guideline. Majalah Farmaseutik. 2021;17(2):243\u20138.","journal-title":"Majalah Farmaseutik"},{"key":"735_CR194","unstructured":"(MHRA). M.a.H.P.R.A., Regulatory considerations for therapeutic use of bacteriophages in the UK. Available online: https:\/\/www.gov.uk\/government\/publications\/regulatory-considerations-for-therapeutic-use-of-bacteriophages-in-the-uk published on 25 June 2025."},{"issue":"12","key":"735_CR195","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/ph16121638","volume":"16","author":"B Zalewska-Pi\u0105tek","year":"2023","unstructured":"Zalewska-Pi\u0105tek B, Therapy\u2014Challenges P. Opportunities and future prospects. Pharmaceuticals. 2023;16(12):1638.","journal-title":"Pharmaceuticals"},{"issue":"9","key":"735_CR196","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41596-020-0346-0","volume":"15","author":"T Luong","year":"2020","unstructured":"Luong T, et al. Standardized bacteriophage purification for personalized phage therapy. Nat Protoc. 2020;15(9):2867\u201390.","journal-title":"Nat Protoc"},{"issue":"8","key":"735_CR197","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/bit.25571","volume":"112","author":"SD Branston","year":"2015","unstructured":"Branston SD, Wright J, Keshavarz-Moore E. A non\u2010chromatographic method for the removal of endotoxins from bacteriophages. Biotechnol Bioeng. 2015;112(8):1714\u20139.","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"735_CR198","doi-asserted-by":"publisher","first-page":"14802","DOI":"10.1038\/srep14802","volume":"5","author":"K Hodyra-Stefaniak","year":"2015","unstructured":"Hodyra-Stefaniak K, et al. Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci Rep. 2015;5(1):14802.","journal-title":"Sci Rep"},{"issue":"8","key":"735_CR199","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/anie.201606181","volume":"56","author":"KS Sunderland","year":"2017","unstructured":"Sunderland KS, Yang M, Mao C. Phage-enabled nanomedicine: from probes to therapeutics in precision medicine. Angew Chem Int Ed. 2017;56(8):1964\u201392.","journal-title":"Angew Chem Int Ed"},{"issue":"3","key":"735_CR200","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/v11030268","volume":"11","author":"B-o Kim","year":"2019","unstructured":"Kim B-o, et al. Phage-derived antibacterials: Harnessing the simplicity, plasticity, and diversity of phages. Viruses. 2019;11(3):268.","journal-title":"Viruses"},{"key":"735_CR201","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10529-007-9346-1","volume":"29","author":"M Skurnik","year":"2007","unstructured":"Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol Lett. 2007;29:995\u20131003.","journal-title":"Biotechnol Lett"},{"issue":"4","key":"735_CR202","doi-asserted-by":"publisher","first-page":"e2041","DOI":"10.1002\/rmv.2041","volume":"29","author":"S Rehman","year":"2019","unstructured":"Rehman S, et al. The dawn of phage therapy. Rev Med Virol. 2019;29(4):e2041.","journal-title":"Rev Med Virol"},{"issue":"1","key":"735_CR203","doi-asserted-by":"publisher","first-page":"100189","DOI":"10.1016\/j.engmic.2025.100189","volume":"5","author":"X Kuang","year":"2025","unstructured":"Kuang X, et al. Applications of bacteriophages in precision engineering of the human gut Microbiome. Eng Microbiol. 2025;5(1):100189.","journal-title":"Eng Microbiol"},{"issue":"2","key":"735_CR204","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4161\/bact.1.2.14590","volume":"1","author":"C Loc-Carrillo","year":"2011","unstructured":"Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111\u20134.","journal-title":"Bacteriophage"},{"issue":"28","key":"735_CR205","doi-asserted-by":"publisher","first-page":"peabq2005","DOI":"10.1126\/sciadv.abq2005","volume":"8","author":"L Meng","year":"2022","unstructured":"Meng L, et al. Nanocapping-enabled charge reversal generates cell-enterable endosomal-escapable bacteriophages for intracellular pathogen Inhibition. Sci Adv. 2022;8(28):peabq2005.","journal-title":"Sci Adv"},{"issue":"10","key":"735_CR206","doi-asserted-by":"publisher","first-page":"e3002341","DOI":"10.1371\/journal.pbio.3002341","volume":"21","author":"MC Bichet","year":"2023","unstructured":"Bichet MC, et al. Mammalian cells internalize bacteriophages and use them as a resource to enhance cellular growth and survival. PLoS Biol. 2023;21(10):e3002341.","journal-title":"PLoS Biol"},{"issue":"1","key":"735_CR207","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12951-024-02576-4","volume":"22","author":"H Wang","year":"2024","unstructured":"Wang H, et al. Phage-based delivery systems: engineering, applications, and challenges in nanomedicines. J Nanobiotechnol. 2024;22(1):365.","journal-title":"J Nanobiotechnol"},{"key":"735_CR208","doi-asserted-by":"publisher","first-page":"675440","DOI":"10.3389\/fphar.2021.675440","volume":"12","author":"VS Gondil","year":"2021","unstructured":"Gondil VS, Chhibber S. Bacteriophage and endolysin encapsulation systems: a promising strategy to improve therapeutic outcomes. Front Pharmacol. 2021;12:675440.","journal-title":"Front Pharmacol"},{"issue":"5","key":"735_CR209","doi-asserted-by":"publisher","first-page":"fuab019","DOI":"10.1093\/femsre\/fuab019","volume":"45","author":"AM Pinto","year":"2021","unstructured":"Pinto AM, et al. The clinical path to deliver encapsulated phages and lysins. FEMS Microbiol Rev. 2021;45(5):fuab019.","journal-title":"FEMS Microbiol Rev"},{"issue":"8","key":"735_CR210","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1111\/1750-3841.15843","volume":"86","author":"Y Xu","year":"2021","unstructured":"Xu Y. Phage and phage lysins: new era of bio-preservatives and food safety agents. J Food Sci. 2021;86(8):3349\u201373.","journal-title":"J Food Sci"}],"container-title":["Gut Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-025-00735-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13099-025-00735-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-025-00735-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:09:54Z","timestamp":1781604594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13099-025-00735-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":210,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1186\/s13099-025-00735-y","relation":{},"ISSN":["1757-4749"],"issn-type":[{"value":"1757-4749","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}